Alnylam Pharmaceuticals (ALNY) Stock
Alnylam Pharmaceuticals (ALNY) closed at $165.04 on Nov 13, 2026; its Tenet Score is 51 of 100 against 313 Healthcare peers.
12 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Previous close
- $165.04
- Nov 13, 2026
- Market cap
- $22.1B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- P/E
- 70.8×
- price ÷ earnings
- 52-week range
- 149.18 – 479.79
- low → high · as of close, Nov 13, 2026
- Tenet Score
- 51/100
- Mixed · 313 Healthcare peers
Industry: Drugs
Alnylam Pharmaceuticals Inc scores 51/100. Mixed. Strongest on growth and quality, value is the soft spot, trading at 71× earnings versus 313 Healthcare peers.
Tenet Score · vs sector
n=313Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ~ Piotroski F-Score
- ~ Munger Compounders
- ✕ Magic Formula
- ✕ Graham Defensive
- ~ Quality Compounder
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic med…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Illumina IncILMN | 52 | $31.3B |
| Roivant Sciences LtdROIV | 43 | $28.6B |
| Insmed IncINSM | 33 | $26.6B |
| United Therapeutics CorpUTHR | 73 | $25.2B |
| Incyte Corp.INCY | 60 | $24.7B |
| Medpace Holdings IncMEDP | 59 | $18.3B |
| Exelixis IncEXEL | 75 | $17.1B |
| Ascendis Pharma A/SASND | 53 | $17.1B |
| Neurocrine Biosciences, Inc.NBIX | 65 | $16.9B |
| Jazz Pharmaceuticals plcJAZZ | 47 | $15.5B |
Compare Alnylam Pharmaceuticals with
Common questions
What sector and industry is Alnylam Pharmaceuticals in?
Alnylam Pharmaceuticals is in the Healthcare sector and the Drugs industry.
What is Alnylam Pharmaceuticals' Tenet Score?
Alnylam Pharmaceuticals' Tenet Score is 51 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.




